Trials / Terminated
TerminatedNCT02346955
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Famewave Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 (CM-24 \[MK-6018\]), administered intravenously as monotherapy and in combination with Pembrolizumab (MK-3475), in participants with selected advanced or recurrent malignancies. Escalating multiple doses will be evaluated to determine the recommended dose for Phase 2 clinical studies.
Conditions
- Non-small Cell Lung Carcinoma (NSCLC)
- Melanoma
- Bladder Cancer
- Colorectal Cancer
- Gastric Cancer
- Ovarian Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM-24 (MK-6018) | humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion |
| BIOLOGICAL | Pembrolizumab (MK-3475) | 200 mg of Pembrolizumab by IV infusion |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2015-01-27
- Last updated
- 2020-08-27
Locations
3 sites across 2 countries: United States, Israel
Source: ClinicalTrials.gov record NCT02346955. Inclusion in this directory is not an endorsement.